Cargando…
Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
OBJECTIVES: To describe the efficacy and safety through 5 years of adalimumab treatment in patients with ankylosing spondylitis (AS), and to identify predictors of remission. METHODS: Patients with active AS were followed up to 5 years during a 24-week randomised, controlled period, followed by an o...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329233/ https://www.ncbi.nlm.nih.gov/pubmed/22128084 http://dx.doi.org/10.1136/annrheumdis-2011-200358 |